Compare Stocks: CHRS, WVE, FTH, and IMMP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHRS Coherus Oncology	$1.21 +2.5%	$1.33	$1.09 ▼ $2.62	$182.31M	0.94	1.28 million shs	1.58 million shs
FTH Sensei Biotherapeutics	$29.74 +5.9%	$32.08	$7.45 ▼ $42.14	$725.34M	-0.28	437,487 shs	356,522 shs
IMMP Prima BioMed	$4.65 -1.3%	$7.09	$4.60 ▼ $70.60	$34.71M	2.21	24,587 shs	10,476 shs
WVE WAVE Life Sciences	$3.70 +1.6%	$5.02	$3.56 ▼ $21.73	$717.26M	-1.3	3.19 million shs	4.07 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHRS Coherus Oncology	+2.54%	-3.97%	-10.37%	-16.55%	-26.22%
FTH Sensei Biotherapeutics	+5.95%	-5.74%	-9.25%	+29.76%	+2,973,999,900.00%
IMMP Prima BioMed	-1.27%	-12.63%	-36.48%	-44.83%	-86.71%
WVE WAVE Life Sciences	+1.65%	-6.33%	-24.49%	-40.89%	-49.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHRS Coherus Oncology	$1.21 +2.5%	$1.33	$1.09 ▼ $2.62	$182.31M	0.94	1.28 million shs	1.58 million shs
FTH Sensei Biotherapeutics	$29.74 +5.9%	$32.08	$7.45 ▼ $42.14	$725.34M	-0.28	437,487 shs	356,522 shs
IMMP Prima BioMed	$4.65 -1.3%	$7.09	$4.60 ▼ $70.60	$34.71M	2.21	24,587 shs	10,476 shs
WVE WAVE Life Sciences	$3.70 +1.6%	$5.02	$3.56 ▼ $21.73	$717.26M	-1.3	3.19 million shs	4.07 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHRS Coherus Oncology	+2.54%	-3.97%	-10.37%	-16.55%	-26.22%
FTH Sensei Biotherapeutics	+5.95%	-5.74%	-9.25%	+29.76%	+2,973,999,900.00%
IMMP Prima BioMed	-1.27%	-12.63%	-36.48%	-44.83%	-86.71%
WVE WAVE Life Sciences	+1.65%	-6.33%	-24.49%	-40.89%	-49.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHRS Coherus Oncology	2.33	Hold	$11.00	809.09% Upside
FTH Sensei Biotherapeutics	2.93	Moderate Buy	$56.25	89.14% Upside
IMMP Prima BioMed	2.40	Hold	$110.00	2,265.59% Upside
WVE WAVE Life Sciences	2.76	Moderate Buy	$22.31	503.04% Upside

Current Analyst Ratings Breakdown

Latest CHRS, WVE, FTH, and IMMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	WVE WAVE Life Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral
9/22/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Sell (D-)
9/16/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/15/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	FTH Sensei Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	IMMP Prima BioMed	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/9/2026	FTH Sensei Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/21/2026	FTH Sensei Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$56.00
8/19/2026	WVE WAVE Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2026	FTH Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/7/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHRS Coherus Oncology	$42.17M	4.43	N/A	N/A	$0.50 per share	2.42
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
IMMP Prima BioMed	$16.40M	2.09	N/A	N/A	$5.67 per share	0.82
WVE WAVE Life Sciences	$42.73M	17.06	N/A	N/A	$3.10 per share	1.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHRS Coherus Oncology	$168.02M	-$1.03	N/A	N/A	N/A	-259.41%	-222.75%	-52.11%	11/5/2026 (Estimated)
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
IMMP Prima BioMed	-$53.82M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	11/9/2026 (Estimated)

Latest CHRS, WVE, FTH, and IMMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	CHRS Coherus Oncology	-$0.25	-$0.19	+$0.06	-$0.13	$14.41 million	$14.31 million
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A
7/30/2026	Q4 2026	IMMP Prima BioMed	N/A	-$1.80	N/A	-$0.0850	N/A	$3.68 million
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHRS Coherus Oncology	0.61	1.77	1.70
FTH Sensei Biotherapeutics	N/A	19.69	19.69
IMMP Prima BioMed	N/A	5.69	N/A
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHRS Coherus Oncology	72.82%
FTH Sensei Biotherapeutics	10.50%
IMMP Prima BioMed	2.32%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
CHRS Coherus Oncology	7.22%
FTH Sensei Biotherapeutics	7.00%
IMMP Prima BioMed	3.07%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHRS Coherus Oncology	144	154.50 million	143.35 million	Optionable
FTH Sensei Biotherapeutics	29	25.84 million	24.03 million	Not Optionable
IMMP Prima BioMed	2,021	7.37 million	7.14 million	Optionable
WVE WAVE Life Sciences	317	197.05 million	149.17 million	Optionable

CHRS, WVE, FTH, and IMMP Headlines

Recent News About These Companies

Wave Life Sciences Earns $12 Million Milestone as GSK Advances Liver Drug

September 30 at 11:47 AM | marketscreener.comM

Wave Life Science Advance Liver-Focused SiRNA Program With GSK; Stock Up

September 30 at 11:47 AM | rttnews.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

September 30 at 11:19 AM | marketbeat.com

Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development

September 30 at 7:30 AM | globenewswire.com

Wave Life Sciences Ltd (WVE)

September 29 at 11:06 PM | uk.investing.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 29 at 2:13 AM | marketbeat.com

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

September 28 at 12:01 PM | zacks.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Should You Sell?

September 28 at 10:59 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Wave Life Sciences (WVE)

September 25, 2026 | theglobeandmail.com

WAVE Life Sciences (NASDAQ:WVE) Stock Picked Up by Analysts at JPMorgan Chase & Co.

September 25, 2026 | americanbankingnews.com

Wave Life Sciences Ltd. lance un essai combiné de phase 2a de WVE-007 avec le tirzépatide dans l’obésité

September 24, 2026 | zonebourse.comZ

Wave Life Sciences Ltd. Initiates Phase 2A Combination Trial of Wve-007 with Tirzepatide for Obesity

September 24, 2026 | marketscreener.comM

JP Morgan Downgrades Wave Life Sciences to Neutral from Overweight

September 24, 2026 | msn.com

Reviewing WAVE Life Sciences (NASDAQ:WVE) & Protalix BioTherapeutics (NYSE:PLX)

September 24, 2026 | americanbankingnews.com

Wave Life Sciences Initiates Phase 2a Trial of Obesity Drug WVE-007 in Combination With Tirzepatide

September 23, 2026 | finance.yahoo.com

Wave Life Sciences avvia trial di fase 2a per l’obesità con WVE-007

September 23, 2026 | it.investing.com

WAVE Life Sciences (NASDAQ:WVE) Trading Down 6.6% - Here's Why

September 23, 2026 | marketbeat.com

JPMorgan Chase & Co. Reiterates "Neutral" Rating for WAVE Life Sciences (NASDAQ:WVE)

September 23, 2026 | marketbeat.com

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

September 23, 2026 | globenewswire.com

Wave Life Sciences Names Monika Vnuk Chief Business Officer

September 22, 2026 | rttnews.com

Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer

September 22, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, WVE, FTH, and IMMP Company Descriptions

Coherus Oncology NASDAQ:CHRS

$1.21 +0.03 (+2.54%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$1.20 -0.01 (-0.83%)

As of 05:46 AM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Sensei Biotherapeutics NASDAQ:FTH

$29.74 +1.67 (+5.95%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$29.66 -0.07 (-0.25%)

As of 09/30/2026 07:30 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Prima BioMed NASDAQ:IMMP

$4.65 -0.06 (-1.27%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$4.68 +0.03 (+0.67%)

As of 04:00 AM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

WAVE Life Sciences NASDAQ:WVE

$3.70 +0.06 (+1.65%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$3.69 -0.01 (-0.27%)

As of 09/30/2026 07:44 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, WVE, FTH, and IMMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, WVE, FTH, and IMMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, WVE, FTH, and IMMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, WVE, FTH, and IMMP Company Descriptions

Coherus Oncology NASDAQ:CHRS

Sensei Biotherapeutics NASDAQ:FTH

Prima BioMed NASDAQ:IMMP

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, WVE, FTH, and IMMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, WVE, FTH, and IMMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, WVE, FTH, and IMMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, WVE, FTH, and IMMP Company Descriptions

Coherus Oncology NASDAQ:CHRS

Sensei Biotherapeutics NASDAQ:FTH

Prima BioMed NASDAQ:IMMP

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools